Pharmaceuticals

SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to sustainability

CAMARILLO, Calif., Dec. 6, 2023 /PRNewswire/ -- SaniSure, a global player in single-use bioprocessing solutions (drug substance and drug product form & fill) and cell & gene therapy is proud to announce that it has been awarded the EcoVadis Silver Rating for its sustainability practices. This rec...

2023-12-06 20:30 3834

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. *  XPOVIO® has received regulatory approvals in  42 countries and regions including Mainland ofChina, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. SHANGHAI AND HONG ...

2023-12-06 17:00 3119

Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%

JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster pr...

2023-12-06 16:55 3135

Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas

KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ -- AstraZeneca's Koselugo (selumetinib)is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas...

2023-12-06 16:46 3146

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-12-06 08:16 5308

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

* Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies * Virtually screens compounds from a universe of >60 billion chemical targets and evaluates synthesis routes for safer, cost-effective, higher-yield drug manufactu...

2023-12-05 21:00 2344

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the approval from Institutional Review Board of Hu...

2023-12-05 16:50 4068

Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development

New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON, Dec. 5, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intellig...

2023-12-05 15:00 2053

Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD)

* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. * ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed inAustralia. ...

2023-12-05 06:00 3826

Latest Updates of Viva's Portfolio Companies

HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2023-12-04 17:55 3644

First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer

SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase III clinical study (JSKN003-302) of anti-HER2 bispecific antibody-drug conjugate JSKN003 for treatment of advanced HER2-low breast cancer. Breast cancer is ...

2023-12-04 14:51 2571

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program inthe Netherlands for its investigational positron emission tomography...

2023-12-04 13:00 2473

Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China

-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis –  -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases are k...

2023-12-04 08:58 5989

The Shanghai Cooperation Organization Traditional Medicine Forum opened

NANCHANG, China, Dec. 1, 2023 /PRNewswire/ -- The Shanghai Cooperation Organization Traditional Medicine Forum opened in Ganjiang New District,Jiangxi Province on November 30, 2023, with the theme of "Inheritance and innovation, unity and cooperation, promoting high-quality development of traditi...

2023-12-01 17:49 3009

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...

2023-12-01 14:41 4004

Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023

ROCKVILLE, Md. and SUZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2023-12-01 12:00 4542

CNN's 'Vital Signs' explores the prospects of phage therapy to treat drug-resistant superbugs

HONG KONG, Dec. 1, 2023 /PRNewswire/ -- Antibiotics have been hailed as a "miracle drug" since the discovery of penicillin in 1928, but now, more bacteria are developing resistance to antibiotics. In 2019, the United Nations estimated nearly 5 million deaths were associated with antimicrobial re...

2023-12-01 11:29 2638

Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis

--Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period-- --Etrasimod was well-tolerated and its safety profile was consistent with prior studies--  --Everest will advance the late-stage study as...

2023-12-01 07:33 4477

Bushu Pharma Recognized with Frost & Sullivan's 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions

Bushu Pharma produces high-quality pharmaceutical and medical devices with sophisticated quality control and supply chain management support that prioritizes customer value. SAN ANTONIO, Nov. 30, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the contract development and manufacturing...

2023-11-30 22:30 2325

Innovent's MSCI ESG Rating Upgraded to A

ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-11-30 21:37 9101
1 ... 89909192939495 ... 184